Thelin sitaxsentan: Preliminary Phase IIb data

In a double-blind, U.S. Phase IIb trial in 35 evaluable patients, 33% and 10% of patients receiving 100 and 50 mg Thelin, respectively, showed an improvement. Also, 20% and 15%, respectively, showed d...